Quick Overview
NHS England has announced the introduction of a cancer diagnostic pathway management service as part of its federated data platform (FDP), set to launch in 2025. This initiative aims to enhance patient care by streamlining access to critical data across various healthcare systems.
Key Features of the Federated Data Platform
- Data Integration: The FDP consolidates data from multiple systems, facilitating quicker access for healthcare staff and enabling more coordinated patient care across England.
- FDP First Policy: The NHS 2025/2026 operational guidance emphasizes that all systems should connect their digital infrastructure to the FDP.
Upcoming Services on the FDP
- Cancer 360: This service will provide a unified patient tracking list (PTL) for those on the cancer diagnosis pathway, featuring active management and performance insights.
- Patient Led Validation: This service empowers patients to confirm their waiting list status directly, enhancing transparency and improving their experience.
- Diagnostics Imaging Scheduler: This tool aims to optimize scheduling for diagnostic processes, thereby increasing productivity and reducing patient wait times.
- Timely Care Hub: This hub will offer a centralized, real-time overview of ward and site activities, aiding in better decision-making and care coordination.
Current Adoption and Impact
- As of February 2025, 96 trusts have signed up for the FDP, a rise from 87 in November 2024.
- These trusts have reported an average 11% reduction in waiting lists, translating to approximately 119 additional patients treated monthly.
- Over one million patients have been treated through the FDP, highlighting its significant role in enhancing care delivery.
Future Goals
NHS England aims to have 85% of all secondary care trusts connected to the FDP by March 2026. The focus remains on improving efficiency, digital transformation, and financial sustainability within the healthcare system.
Controversies Surrounding the FDP
The FDP has faced scrutiny, particularly regarding the £330 million contract awarded to US company Palantir in November 2023. Concerns have been raised about the procurement process and the company’s ethical background, given its associations with various government agencies.